Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort

Fertility Disorders Clinical Trial

Official title:

Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort: a Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03238092
• Other study ID #: 67491417800005327
• Status: Not yet recruiting
• Phase: Phase 3
• First received: August 1, 2017
• Last updated: August 1, 2017
• Start date: August 2017
• Est. completion date: March 2018

Study information

• Verified date: August 2017
• Source: Hospital de Clinicas de Porto Alegre
• Contact: Camila Bessow, MD
• Phone: +5551992723620
• Email: k.bessow[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In vitro fertilization(IVF) with Gonadotropin-releasing hormone (GnRH) antagonist is one of the most used protocol for the treatment of infertile couples nowadays. Despite several advantages over GnRH agonist, the antagonist may be associated with a slightly reduction in pregnancy rates.

Several medications have been tested in order to increase ovarian response to ovulation induction, including estradiol and testosterone. A clinical trial in women with IVF indication will be performed and this women will be randomly assigned to receive topic testosterone, oral estradiol or no pre-treatment prior to IVF with human Chorionic Gonadotropin (hMG) and GnRH antagonist. The primary endpoint will be the size and number of follicles on the beginning of the cycle, after pre-treatment.

Description:

One of the key-words to a successful IVF it is the response to the ovarian controlled stimulation. Nowadays, one of the most common protocols includes exogenous gonadotropins and GnRH antagonist, followed by IVF. The GnRH antagonist avoids the premature peak of LH and has advantages in relation to the GnRH agonist; however it might have a negative effect over the pregnancy rate. One possible explanation is the heterogeneity of the follicular cohort at the moment of ovarian puncture, due to the rise of FSH at luteal-follicular transition. The estrogen can inhibits this rise of Follicle-Stimulating Hormone (FSH), resulting in a more synchronic cohort. Previous studies have demonstrated a reduction in the cancellation rates with estradiol in the luteal phase of the cycle prior to the beginning of IVF using GnRH antagonist protocol, with a trend towards better quality of transferred embryos and better implantation rates when compared to the standard protocol with antagonist. The use of androgens is based on the assumption that they generate an increase in FSH receptors in the granulosa cells, increase in follicular growth and estrogen production, according to animal and human studies. Despite promising initial results, further studies are needed to evaluate the benefit of testosterone as a pretreatment in women undergoing IVF.

The study protocol is the following: Around the 20th day of the cycle prior to the choice of IVF, transvaginal pelvic ultrasound and serum progesterone dosage will be performed in all patients. After confirmation of ovulation and no contraindications for the continuation of the study, according to the randomization, testosterone gel, estradiol oral or no treatment will be initiated. Both medications will be continued until the first day of subsequent menstruation. After the menses, between the second and third day of the cycle, a new transvaginal ultrasound will be performed and blood tests will be collected for the dosage of FSH, Luteinizing Hormone (LH), progesterone and estradiol. On the same day, subcutaneous hMG (Menopur®) will be started at a dose between 150 and 300 IU / day, according to age and HAM, which will be subsequently adjusted according to the ovarian response on serial ultrasonography. When the largest follicle reaches a mean diameter of 14 mm, the GnRH antagonist (Orgalutran ®) will be initiated to prevent early LH peak, and monitored follicular growth with echography every 1-2 days. HCG will be administered at a dose of 10,000 IU (Choriomon®) when three or more follicles reach a mean diameter of 17 mm. After 36h, follicular puncture will be performed transvaginally, under general anesthesia. Embryo transfer will occur between the third and fifth day after in vitro fertilization. Luteal support will be given with administration of progesterone 600 mg / day vaginally, initiated after the transfer and maintained until the first trimester of pregnancy if it occurs. Serum beta-HCG measurement will be performed on the 12th day after transfer, for evaluation of pregnancy implantation. Clinical gestation will be considered when there is evidence of intrauterine embryo with cardiac beats present on the ultrasound, after 6 weeks of transfer of the embryo (s).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 26
• Est. completion date: March 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Regular cycles (between 25-34 days)

• In vitro fertilization indication for male cause, unexplained infertility or tubal factor

• Both ovaries

• Thyroid-stimulating hormone(TSH) < 2,5 mU/L

• Anti-Müllerian hormone (AMH) between 1-5 ng/ml

• Body Mass Index (BMI) < 30

Exclusion Criteria:

• Ovarian surgery

• Endometriosis

• Endocrinology or metabolic disorder

• Polycystic ovary syndrome (PCOS)

• Poor Ovarian Response (according to Bologna criteria)

Related Conditions & MeSH terms

• Fertility Disorders

Intervention

Drug:
• Testosterone
testosterone gel daily during the late luteal phase.
• Estradiol
oral estradiol during the late luteal phase.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospital de Clinicas de Porto Alegre

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of antral follicles	Number of follicles measured by transvaginal ultrasound during the first or second day after menstruation	15 days after intervention
Secondary	follicular cohort homogeneity	The comparison of medium follicular diameter (also measured by transvaginal ultrasound) of all the follicles during the first or second day after menstruation	15 days after intervention
Secondary	metaphase II oocytes	the number of metaphase II oocytes	30 days
Secondary	gonadotrophin use	number of units of gonadotrophin used during the in vitro fertilization protocol	30 days
Secondary	number of embryos	the number of embryos assessed during the in vitro fertilization	30 days
Secondary	pregnancy	clinical pregnancy, defined by the evidence of intrauterine embryo in the ultrasound	6 weeks